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Following the West African Ebola virus disease (EVD) outbreak of 2013–2016 and more
recent EVD outbreaks in the Democratic Republic of Congo, thousands of EVD survivors
are at-risk for sequelae including uveitis, which can lead to unremitting inflammation and
vision loss from cataract. Because of the known risk of Ebola virus persistence in ocular fluid
and the need to provide vision-restorative, safe cataract surgery, the Ebola Virus Persis-
tence in Ocular Tissues and Fluids (EVICT) Study was implemented in Sierra Leone. During
implementation of this multi-national study, challenges included regulatory approvals, mobi-
lization, community engagement, infection prevention and control, and collaboration
between multiple disciplines. In this report, we address the multifacted approach to address
these challenges and the impact of implementation science research to address an urgent
clinical subspecialty need in an outbreak setting.
Methodology/Principal findings
Given the patient care need to develop a protocol to evaluate ocular fluid for Ebola virus
RNA persistence prior to cataract surgery, as well as protocols to provide reassurance to
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ophthalmologists caring for EVD survivors with cataracts, the EVICT study was designed
and implemented through the work of the Ministry of Health, Sierra Leone National Eye Pro-
gramme, and international partnerships. The EVICT study showed that all 50 patients who
underwent ocular fluid sampling at 19 and 34 months, respectively, tested negative for
Ebola virus RNA. Thirty-four patients underwent successful cataract surgery with visual acu-
ity improvement. Here we describe the methodology for study implementation, challenges
encountered, and key issues that impacted EVD vision care in the immediate aftermath of
the EVD outbreak. Key aspects of the EVICT study included defining the pertinent questions
and clinical need, partnership alignment with key stakeholders, community engagement
with EVD survivor associations, in-country and international regulatory approvals, study site
design for infection prevention and control, and thorough plans for EVD survivor follow-up
care and monitoring. Challenges encountered included patient mobilization owing to trans-
portation routes and distance of patients in rural districts. Strong in-country partnerships and
multiple international organizations overcame these challenges so that lessons learned
could be applied for future EVD outbreaks in West and Central Africa including EVD out-
breaks that are ongoing in Guinea and Democratic Republic of Congo.
Conclusions/Significance
The EVICT Study showed that cataract surgery with a protocol-driven approach was safe
and vision-restorative for EVD survivors, which provided guidance for EVD ophthalmic sur-
gical care. Ophthalmologic care remains a key aspect of the public health response for EVD
outbreaks but requires a meticulous, yet partnered approach with international and local in-
country partners. Future efforts may build on this framework for clinical care and to improve
our understanding of ophthalmic sequelae, develop treatment paradigms for EVD survivors,
and strengthen vision health systems in resource-limited settings.
Introduction
The West African Ebola virus disease (EVD) outbreak from 2013–2016 led to the largest EVD
survivor cohort, predominantly within the most affected countries of Sierra Leone, Liberia,
and Guinea [1,2]. In the aftermath of the West African outbreak, EVD survivor sequelae were
increasingly recognized with findings that included uveitis, arthritis, mental health disorders,
abdominal pain, and the risk of Ebola virus (EBOV) persistence in immune privileged organs
[3–7]. Three additional EVD outbreaks have occurred in the Democratic Republic of Congo
(DRC) during 2017–2020, including an outbreak in eastern DRC that resulted in 3,200 cases
and over 2,000 deaths [8]. During February 2021, EVD outbreaks once again emerged in
Guinea and in Democratic Republic of Congo, emphasizing the mandate to continue to
understand the clinical implications of EVD, including EVD survivor sequelae and clinical
research methodology.The thousands of EVD survivors within West Africa and the DRC
emphasize the importance to broaden our understanding of the spectrum of clinical findings,
mechanism of disease, and management algorithms for treating EVD sequelae. While
advances have been made since the West African EVD outbreak with the availability of a
licensed Ebola vaccine and proven therapies for EVD [9–11], further development of care pro-
tocols and consensus for EVD survivor health care remains a key issue.
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Uveitis, an ocular inflammatory disease with the potential for vision compromise and
blindness if untreated, has been identified with a particularly high prevalence in EVD survi-
vors, ranging between 13–34% in prior retrospective series [4,12–14]. Recently, the National
Institutes of Health-funded PREVAIL Study, a prospective longitudinal natural cohort study
of EVD survivors in Liberia, identified a 26% prevalence of uveitis, that increased to 33% at
one-year follow-up. The prevalence of uveitis in EVD survivors was higher than in controls
who were close-contacts of EVD cases, but notably, the control group had a higher prevalence
of uveitis at baseline than reported in other epidemiologic studies (i.e. 12% prevalence of uve-
itis in controls at baseline and 15% at 1-year) [3]. Among EVD survivors who developed uve-
itis in Liberia, we observed that nearly 40% of patients with uveitis were blind due to a variety
of complications including cataract, retinal scarring involving the macula, and optic nerve dis-
ease [4].
Cataract has been observed in 5–10% of EVD survivors [3,4]. However, vision loss due to
cataract is reversible and presents an opportunity for vision restoration to improve work pro-
ductivity, enhance an individual’s activities of daily living, and promote socialization. The
potential reduction of stigmata in EVD survivors where dense white cataract may be visible is
a strong consideration for the well-being of the individual. Given that Ebola virus (EBOV) per-
sistence had been identified in ocular fluid in association with sight-threatening panuveitis [6],
there has been uncertainty regarding the risk of EBOV persistence in eye fluid and the best
approach for invasive eye surgery. These considerations were particularly important for oph-
thalmologists, eye care nurses and providers to safely restore vision for EVD survivors through
eye surgery with a measured approach.
To address these questions, we designed the Ebola Virus Persistence in Ocular Tissues and
Fluids (EVICT) Study [15]. The purpose of the EVICT Study was to develop a protocol-driven
approach to cataract surgery, staged to first assess ocular fluid for evidence of EBOV RNA per-
sistence by RT-PCR, followed by cataract surgery for survivors whose ocular fluid tested nega-
tive for EBOV RT-PCR. During the EVICT study, fifty patients were enrolled and underwent
ocular fluid sampling to evaluate EBOV RNA persistence in ocular fluid. All patients tested
negative for EBOV RNA by RT-PCR in the aqueous humor (n = 49) or vitreous humor (n = 1)
at a median of 19 months in Phase 1 of ocular fluid sampling and 34 months after EVD diag-
nosis in Phase 2 of ocular fluid sampling. Thirty-four patients eventually underwent manual
small incision cataract surgery (MSICS) with improvement in median preoperative visual acu-
ity from only hand motions to 20/30 at three-month postoperative follow-up (p<0.001) [15].
The clinical details are described in prior work.
Herein, we describe the implementation of this study including the formal research design,
partnerships, implementation and lessons learned through vision research in a resource-lim-
ited setting. During the development and implementation of the EVICT study, the imperative
to restore vision safely was aligned with research questions including clinical and postoperative
evaluations and coordinated with advanced laboratory testing with Sierra Leone and interna-
tional partners. Prior reports have documented some of the challenges of performing research
in outbreak settings for reasons including supply shortages, insufficient health personnel,
potential for EBOV infections in health care personnel and a depleted workforce, as well as sys-
tems of care conducive to both clinical care and research [16–18]. As research questions arise
in emergent outbreak settings, a thoughtful approach to partnerships with local health care
providers, identification of key clinical research questions, community engagement, rigorous
study design, and implementation in resource-limited settings is needed.
Our description of the detailed implementation of the EVICT Study aims to inform oph-
thalmologists, infectious disease specialists and public health specialists regarding the unique
challenges, lessons learned, and preparedness measures for EVD outbreaks and emerging
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infectious disease outbreaks with ophthalmic sequelae. Beyond the clinical care needs for EVD
survivors, the implementation of the EVICT Study also provides key learnings for prepared-
ness measures for clinical research and the provision of subspecialty care, invasive procedures
and considerations for assessing immune privileged sites (e.g. eye, central nervous system,
reproductive organs) that may harbor infectious pathogens.
Methods
Partnership alignment: A reflection of momentum from the acute EVD
outbreak
Prior to initiation of the EVICT Study, the Ministry of Health and Sanitation (MOHS), Sierra
Leone National Eye Programme, in partnership with the World Health Organization, Partners
in Health, Emory University, GOAL, Save the Children and Medecins sans Frontieres organi-
zations (Belgium, France, Switzerland) organized and implemented the National Eye Program
screening program to perform ophthalmic examinations on a countrywide basis [19,20]. This
was coordinated with the Comprehensive Programme of EVD Survivors (CPES) through the
Program Implementation Unit of MOHS. The Sierra Leone Association of Ebola Survivors
(SLAES) was organized during the acute EVD outbreak to advocate for their membership for
systemic and ophthalmic health services, and SLAES played a key leadership and coordination
role throughout the National Eye Program and the EVICT Study. Through the National Eye
Screening program, which evaluated>3500 EVD survivors throughout Sierra Leone, individ-
uals with uveitis were diagnosed and treatment was initiated. In addition, EVD survivors with
cataract were identified for later screening in the EVICT Study. Moreover, EVD survivors who
needed specialty care (e.g. oculoplastic surgery, corneal disease, retinal disease processes) were
also identified and referred to providers where available.
The scope of work was discussed with laboratory partners, given the technical challenges
potentially associated with a small volume of ocular fluid sample that was anticipated for
molecular testing of EBOV RNA by RT-PCR. Additional testing that for other infectious etiol-
ogies of uveitis that was not widely available in Sierra Leone included serologic testing for
Ebola IgG, rapid plasma reagin (RPR), and HIV. Molecular pathologic evaluation was facili-
tated by the United States partners, necessitating Sierra Leone government approvals (i.e.
Chief Medical Officer, Pharmacy Board, Office of National Security), along with Centers for
Disease Control and Prevention import permits and appropriate Materials Transfer Agree-
ments between institutions to facilitate transport of laboratory specimens. Other international
partners who were in-country during the EVD outbreak (i.e. China Centers for Disease Con-
trol) also provided technical guidance for the study design, as well as capacity for additional
immunologic evaluation of EVD survivors in the EVICT Study. Table 1 summarizes the key
stakeholders, roles of each of the multi-national partners, and key processes of the EVICT
program.
Ethics and institutional review board approvals
Ethics and Institutional Review Board approvals were obtained from the MOHS and Emory
University for the EVICT Study. Participants provided written informed consent after a thor-
ough discussion of the risks, beneftis, and alternatives to participation including the key point
that their ophthalmic care would be provided regardless of participation in the EVICT study.
An opportunity to ask questions through an interpreter was given prior to obtaining consent
to ensure consent. Consent was obtained for minors less than 6 years old via written consent
from parents or guardians. Verbal assent was obtained for children 6–10 years old in addition
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Table 1. Overview of EVICT study implementation, host and visitor country considerations�.
Key Process of Clinical Research and Goals (Bulleted) Stakeholders involved/Steps Taken
Definition of the patient care question and approach
• Identify the problem and impact (i.e. Ebola virus
persistence in patients needing cataract surgery)
• Outline the approach to patient care
• Patients–Ebola survivors and close-contacts of Ebola
survivors with potential exposure
• Ministry of Health and Sanitation National Eye
Program ophthalmologists, eye surgeons and mid-level
providers
• Emory Ophthalmology, Infectious Disease specialists
• Partners in Health and multiple non-governmental
organizations (NGOs)
• World Health Organization and public health experts
• Centers for Disease Control and Prevention
Ethics and Institutional Review Board approval
• Independent review of benefit of study, safety, and
informed consent process
• Host in-country and external approvals
• Annual review to ensure amendments, consents and
protocol up-to-date
• Sierra Leone Ministry of Health and Sanitation Ethics
and Institutional Review Board Committee
Emory University Institutional Review Board
Partnership Alignment
• Programmatic support
• Identification of patient populations and need
• Patient mobilization
• Technical guidance and expertise
• Public health awareness and guidanace
• Guidance for patient sensitivity, study awareness,
and sociocultural considerations
• Ministry of Health and Sanitation National Eye
Programme, Sierra Leone
• Ministry of Health and Sanitation Chief Medical
Officer, District Medical Officers, and medical
leadership
• Sierra Leone Association of Ebola Survivors/Survivor
Health Advocates
• Emory Ophthalmologists, Infectious Disease specialists
• World Health Organization Global Outbreak Alert
Response Network
• Lead NGO–Partners in Health
• Multiple NGOs involved in Ebola response–MSF,
GOAL, Save the Children
Laboratory Alignment
• Ensure accurate testing to answer clinical research
questions related to patient care
• Quality control for specimen handling (i.e. infectious
pathogen transport, temperature regulation)
• Kenema Government Hospital Lassa Fever laboratory
• Centers for Disease Control and Prevention (Materials
Transfer Agreement for Import/Export and laboratory
guidance)
• Kissy United Methodist Church in-hospital laboratory
• China Centers for Disease Control and Prevention
• United States Army Medical Research Institute of
Infectious Diseases (US AMRIID)
Site Selection and Approval
• Verification of adequate space for procedure, ocular
fluid sample handling and storage
• Verification of site for infection prevention and
control precautions
• Local hospital, medical board, and institutional
approvals prior to study
• Ministry of Health and Sanitation National Eye
Programme Ophthalmologists
• Lowell and Ruth Gess Eye Hospital leadership
• Kissy United Methodist Church Medical Board
• Non-government organization guidance and support
(i.e. Central Global Vision Fund)
• Emory University Infectious Disease and
Ophthalmology service verification of site and study
design
Patient Mobilization and Program Implementation
• Ensure adequate patient recruitment
• Address patient clinical service needs
• Promote understanding of research protocol, clinical
need, potential benefits and risks to Ebola survivors
• Communicate program and support informed
consent for patients with adequate interpretation
• Ministry of Health and Sanitation, Sierra Leone–
Comprehensive Program for Ebola Survivors
• Sierra Leone Association of Ebola Survivors and
Survivor Health Advocates
• Partners in Health and NGOs involved in Ebola
outbreak response
(Continued)
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to parent/guardian assent, and written assent was obtained for children 11–17 years old in
addition to parent/guardiain assent, consistent with Emory University and MOHS Ethics and
Institutional Review Board policies. The participants in this manuscript have given written
informed consent (as outlined in PLOS consent form) to publish case details and the clinical
environment.
A memorandum of understanding and detailed work plan between key partners was
drafted to ensure clear resource management, organization and assurance of tasks to be com-
pleted. Given that EVD survivors are considered a vulnerable population, multiple conversa-
tions with SLAES leadership were helpful to properly communicate the goals of the study,
which were driven by the clinical need, the uncertainty surrounding the question of whether
EBOV could persist in the eye at long-term follow-up, and impact of reporting the clinical out-
comes and scientific findings. The information gathered from assessing ocular fluid for Ebola
viral persistence prior to cataract surgery would potentially inform guidance for ophthalmic
care for future EVD outbreaks. During the meetings with SLAES leadership, these ideas were
communicated, particularly related to the importance of ocular fluid sampling prior to cataract
surgery, postoperative follow-up and study design.
Patient eligibility, recruitment and mobilization
The Sierra Leone Ministry of Health National Eye Screening Program for Ebola Survivors,
Partners in Health, and the Sierra Leone Association of Ebola Survivors (SLAES) were the key
partners for the recruitment of patients in the EVICT Study. Patients with vision impairment
and were diagnosed with cataract through the National Eye Screening program were offered
an EVICT screening evaluation [20]. In addition, any EVD survivor who was known to the
SLAES organization as having symptoms of cataract (i.e. blurred vision, glare, haloes, or loss of
Table 1. (Continued)
Key Process of Clinical Research and Goals (Bulleted) Stakeholders involved/Steps Taken
Preoperative Ophthalmic Examination, EVICT Study
Procedures
• Design workflows for high-volume EVICT patient
screening in urban and rural settings
• Conduct visual acuity, ophthalmic exam and
diagnostic procedures
• Perform ocular fluid sampling for EVD survivors
• Perform cataract surgery using manual small incision
cataract surgery
• Provide opportunities for education for local mid-
level providers, and ophthalmologists from Sierra
Leone and Guinea
• Ensure long-term follow-up for patients following
cataract surgery
• Ministry of Health and Sanitation Sierra Leone
ophthalmologists and mid-level providers
• Ophthalmologist based at Lowell and Ruth Gess Eye
Hospital
• Research administrative lead from Lowell Ruth Gess
Eye Hospital
• Ophthalmic technicians from Lowell and Ruth Gess
Eye Hospital
• Emory University ophthalmologists and partners
• Emory University Infectious Disease physicians for IPC
monitoring during study procedure
• Kissy United Methodist Church Hospital anesthesia
technician
• Other study personnel: Hygienist, Phlebotomist
• Visiting ophthalmologists from Guinea
�Key process steps of clinical research and their goals are shown. These steps involved stakeholders in-country and
visitor country organizations and institutions involved in implementing the clinical research project. Steps included
definition of key patient needs and approaches, ethical and regulatory approvals, partnership alignment, laboratory
alignment, site selection, patient mobilization, patient protection, and sociocultural context for proper program
implementation of the technical demands of the project (i.e. patient evaluation, procedures, surgery, and ensuring
appropriate long-term follow-up).
https://doi.org/10.1371/journal.pone.0252905.t001
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color vision) was eligible for a screening evaluation. A full dilated ophthalmic evaluation was
performed by a trained ophthalmologist, and EVD survivors were offered enrollment if they
met inclusion criteria. Details of the evaluations and site design have been described previously
[15].
The ocular fluid sampling and cataract surgery were offered in two phases primarily due to
logistical challenges surrounding transportation. In Phase 1, survivors were recruited primarily
from major urban areas and regions with a high EVD burden and included Western Area
Urban, Western Area Rural, and Port Loko. In Phase 2, EVD survivors were screened from
outlying rural districts outside the original areas of recruitment (e.g. Bombali, Tonkolili, Puje-
hun, Kenema and others).
Study site and design: Leveraging infectious disease, public health, and
ophthalmology expertise for infection control
Site selection of the Lowell and Ruth Gess Eye Hospital (LRGEH) involved partnered deci-
sion-making and approvals by the Kissy United Methodist Church LRGEH Medical Board,
Central Global Vision Fund, and Christian Blind Mission International, and each played a key
role in the infrastructural maintenance, personnel and operations of the study sites. The
impact of the study for EVD survivors and the diligent preparations needed for patient care,
and adherence to infection control principles for all of the stakeholders were emphasized. The
overall site and ophthalmic procedure room design for infection prevention and control was
developed with Emory and West African ophthalmologists, public health experts from the
WHO, and the Emory University Serious Communicable Disease Unit infectious disease phy-
sicians (S1 File). In addition, we utilized WHO Guidelines in EVD patient care for infection
control precautions [21].
For the ophthalmic procedure suite, a unidirectional flow design was implemented so that
donning could occur prior to entry and PPE doffing could be performed and monitored prior
to exit via a transition zone (Fig 1). In each area, a physician trained in high-level PPE for the
care of EVD patients monitored donning, performance of the ophthalmic procedure, and doff-
ing. Alcohol-based hand sanitizer was present in multiple locations to ensure proper disinfec-
tion, particularly when handling ocular specimens that potentially contained infectious
material.
Personal protective equipment
The PPE for physicians, patients, and assistants was determined by the specific risk level for
EBOV exposure, proximity to the procedure site, and the splash potential. For example, the
ophthalmologists who were performing anterior chamber paracentesis donned full PPE for
the procedures. These included a PAPR mask, fluid impervious Tyvek suit with shoe covers,
and surgical gloves at all times. PPE for patients included a bouffant or surgical cap, apron and
shoe covers. Observers in the room stood approximately six feet away from the table on the
contralateral side of the patient to enable procedure observation while maintaining a safe dis-
tance during the procedure and after specimen transfer. The infectious disease physicians
wore a bouffant cap or surgical cap, protective eyewear, aprons, shoe covers and gloves for
specimen transfer through a specimen window (Fig 1).
EVICT ophthalmic screening visit
Because of the volume of patients who were screened, a system of vision examination was
developed in modular stations. The full ophthalmic examination was divided into modular sta-
tions, allowing for a design of the space, expertise, and equipment necessary to carry out
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screening operations with basic ophthalmic equipment (Fig 2). The stations included 1) His-
tory-taking; 2) Visual Acuity; 3) Ocular Vitals (Pupil, Motility, Visual Fields) where patients
are also dilated; 4) Slit lamp examination and dilated examination with indirect ophthalmos-
copy. These stations provide a way to segregate the portions of the exam both for clinic flow
Fig 1. Photograph composite of EVICT study site. The EVICT study site was prepared with input from the Ministry of Health and Sanitation
National Eye Programme, Sierra Leone input, along with guidance from Emory Ophthalmology, Infectious Diseases specialists, World Health
Organization, and public health officials. A donning station was designed with powered air purifying respirator (PAPR) hoods, fluid impervious Tyvek
suits, and shoe covers at the entryway to the procedure rom (A). The procedure room created from tarp partitions hooked from the ceiling, contained
only the minimum necessary supplies for each ocular fluid sampling procedure with visibility to the donning area, marked by duct tape (B, black
asterisks). A specimen window is on the wall of the tarp and duct tape (red asterisks) marks the doffing area for providers to exit via the transition zone.
A specimen window is open to a clean area where ocular fluid samples are passed after double-bagging and disinfection of the specimen container (C).
Visible signage for doffing is labeled and visible at the transition zone with a duct tape large arrow (D) with access to hand disinfection in the transition
zone (E). An emergency shower facility is available in the event of contamination. Photographs A-D courtesy of Mr. Andrew Gess.
https://doi.org/10.1371/journal.pone.0252905.g001
Fig 2. Slit lamp photography and high quality iPhone photographs through slit lamp oculars. Ophthalmic
screening for cataract included evaluation of visual acuity, intraocular pressure measurement, slit lamp examination,
dilated funduscopic examination and ultrasonography. While advanced photography was largely unavailable,
photography could be performed with an iPhone and the ocular of the microscope (A). Resultant iPhone photographs
through the ocular of the microscope showed white mature cataract (B, C) and posterior synechiae in eyes of Ebola
virus disease survivors indicating chronic untreated inflammation (C, yellow arrows). High-resolution photography
through operator stabilization enables visualization of anterior capsule crenations and cortical clefts within
intumescent cataract.
https://doi.org/10.1371/journal.pone.0252905.g002
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and opportunities for teaching (e.g. learner(s) paired with an ophthalmologist/examiner at
each station). Depending on the numbers of fully trained personnel and equipment available,
these stations can be modified for both mobile clinics and free-standing eye centers and
clinics.
For patients who had a visually significant cataract (i.e. impeding activities of daily living or
work), enrollment into the EVICT Study was offered. The complexity of the consenting pro-
cess, ophthalmic examination, and ocular fluid sampling procedures required a coordinated
effort on separate study days (i.e. clinic days for consenting and examination; procedure days
for ocular fluid sampling, storage, and organization of patient samples for distant shipment).
The ophthalmic examination and study screening were performed at the beginning of the
week followed by ocular fluid sampling at a scheduled date. Once a negative EBOV RT-PCR
result was received, the patient could proceed with cataract surgery, which occurred at a later
date.
Procedure day setup
The procedure day involved patient processing through several stations prior to the procedure
and post procedure monitoring, including (consent and counseling), phlebotomy station, fol-
lowed by the ocular fluid sampling, and post procedure observation.
Consent and counseling
During consent and counseling, it was vital to have interpreters available for a discussion of
risks, benefits, and alternatives to the protocol enrollment and performance of the procedure.
In addition, patients were given the opportunity to ask questions related to any part of the pro-
cedure and voice understanding. Interpretation involved individuals who could speak one of
several languages (Krio, Mende, Temne, and Limba). However, in rare situations a dual inter-
preter system was needed (e.g. English to Temne; Temne to one of several dialects). During
the counseling and consent process, the environment where the patients would have their pro-
cedures performed was also discussed. Specifically, an EVD survivor who previously had
undergone ocular fluid sampling counseled the EVD survivors that the physician would be
wearing PPE for safety of everyone. This discussion helped to reduce potential post-traumatic
symptoms, anxiety, or fear related to the patient’s prior hospitalization in an Ebola Treatment
Unit. After the extensive counseling process, a sticker for identification was placed above the
ocular procedure site and later verified in the procedure room. The consent process also
included an assent process for children between 13 and 18 years old approved by Sierra Leone
and Emory IRBs.
Phlebotomy and laboratory assessments
Following the full informed consent process, the patient was escorted to the phlebotomy area
with an interpreter, as well as a guardian when needed. Peripheral blood was collected for sero-
logical testing, including Ebola IgG and IgM to confirm EVD survivor status, Lassa IgG and
IgM, and other etiologies of uveitis (RPR, HIV), as well as for immunologic assays. Laboratory
assessments were limited due to lack of reagents for other diseases that could also be associated
with uveitis (e.g. testing was not performed for sarcoidosis with ACE and lysozyme).
Ocular fluid sampling/Anterior chamber paracentesis and aspiration
The personnel involved in the procedure included two Uveitis and Retina fellowship-trained
ophthalmologists (i.e. for performance of the procedure and assistance), an infectious disease
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physician for monitoring donning and doffing PPE and specimen handling, and observers,
that included eye care providers/health care workers from both Sierra Leone and Guinea. The
details of the procedure have been described previously but included ocular surface conjuncti-
val pre and post anterior chamber paracentesis and aqueous humor or vitreous fluid sampling
[15].
One of the challenges for the procedure was the available dim lighting. To improve stereop-
sis for the ocular fluid sampling procedure, a penlight shined at an approximately 30 degree
angle from the horizontal midline was sufficient for the operator to visualize the anterior
chamber depth for needle placement to avoid inadvertent trauma to the lens and the anterior
surface of the capsule enveloping the cataractous lens (Fig 3).
Specimen handling included strict infection prevention and control precautions with dou-
ble-bagging and external disinfection of all biospecimen containers. Following transfer of the
specimen through a specimen ‘window’ that was 2 feet by 2 feet square cut out of the tarp (Fig
1). The specimen receiver, who was also gloved, handled the specimen, disinfected the bag and
placed the specimen in cold chain storage, and also recorded key observations during the pro-
cedure (i.e. volume of fluid obtained, complications). Following the procedure completion, the
eye was irrigated free of anti-septic solution and an eye patch and eye shield were applied. The
patient exited through the transition zone where their hands were disinfected prior to removal
of their PPE. For health care provider doffing, this process was monitored by the ID physician
to ensure that no exposure occurred. This included chlorine spray disinfection of the gloves
and disinfection after removal of shoe covers. The health care provider walked through a mat
immersed in chlorine before exiting. All other individuals involved in the procedure followed
appropriate IPC precautions during the exit from the procedure room.
Fig 3. EVICT cataract surgery room setup. Aqueous humor and vitreous procedures were performed with an
operator and assistant in full personal protective equipment (PPE). Infectious Diseases specialist monitoring was
essential to ensure proper infection prevention and control precautions during the procedure, with specimen handling
and during the donning and doffing of PPE. Sierra Leone observers and technical staff in PPE were also present for
interpretation and observation of the procedure for training purposes. Following the ocular fluid sampling procedure,
once Ebola virus RT-PCR testing of aqueous humor yielded negative results, manual small incision cataract surgery
MSICS) could be performed in surgical PPE as shown. A video monitor was attached to the surgical microscope for
additional education and teaching purposes.
https://doi.org/10.1371/journal.pone.0252905.g003
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Specimen handling and transfer
All specimens in their container and biohazard specimen bags were placed in a 4˚ tempera-
ture-monitored refrigerator. Because the receiving laboratory (i.e. Kenema Government Hos-
pital Lassa Hemorrhagic Fever laboratory) was four hours away from the LRGEH site, the
specimens were refrigerated overnight at a 4˚ temperature-monitored refrigerator prior to
pick-up by a medical courier trained in specimen delivery of highly infectious pathogens. All
specimens were stored in a dual container system with ice packs (i.e. double-bagged and stored
in a medical cool box to ensure cold chain transport).
Ebola virus RT-PCR testing
Following receipt of the conjunctival swab specimens, aqueous or vitreous humor specimens,
a member of the ophthalmology team was contacted by the KGH laboratory team to confirm
receipt of the samples. The assays performed consisted of an in-house assay for EBOV
RT-PCR with primer targets that have been described previously [22]. Laboratory results were
communicated to the ophthalmology care team; following confirmation of a negative EBOV
RT-PCR result, the patient underwent manual small incision cataract surgery (MSICS).
Manual Small Incision Cataract Surgery (MSICS)
MSICS procedures were performed by an in-country ophthalmologist with PPE and infection
prevention and control guidance from infectious disease specialists. The cataract surgery was
performed in a room designated for infection control purposes (i.e. not in the main operating
theater) educational observation, and specimen collection (Fig 3). Although ocular specimens
(conjunctiva, aqueous humor) collected in phase 1 of the EVICT study tested negative for
EBOV by RT-PCR, whether the cataract lens, lens capsule or vitreous could have EBOV persis-
tence was unknown. For this reason, handling of these specimens as well as aqueous humor
sampling was performed with IPC precautions as in Phase 1 of the study. Specifically, after any
specimen was harvested from the eye (i.e. ocular fluid, lens capsule, cataract lens), the syringe
(i.e. for ocular fluid) or container with the specimen formalin (i.e. for tissue specimens) was
wiped down with hospital grade disinfectant and then double-bagged for transport to the
KGH laboratory.
Postoperative follow-ups
Patients were evaluated at postoperative day 1 and at scheduled intervals (i.e. 1 week, 2 weeks,
1 month, 3 months and 5–6 months). For patients with substantial ocular inflammation identi-
fied postoperatively, more frequent follow-up was recommended. Feedback from the in-coun-
try ophthalmologist and United States-based team via teleconference or email on a bimonthly
basis was implemented to communicate clinical care questions during the postoperative
period. A SLAES medical representative communicated with patients regularly so that patients
with new symptoms could also be evaluated by the Sierra Leone ophthalmology care team if
needed.
Challenges and lessons learned. While there were challenges to bring together multiple
partners to design, implement, and carry out this multifaceted study in a resource-limited set-
ting, a number of lessons learned are applicable to ophthalmic research and care related to
acute EVD and sequelae, as well as to other emerging infectious diseases. While implementa-
tion of clinical research protocol in well-resourced countries can require more time than
expected due to a multiplicity of factors (e.g. delays in funding, study design development,
patient recruitment, or regulatory approvals), our partnership faced additional challenges
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given the resource-limited environment (e.g. patient transportation, stable electricity and
power, facility design with spatial constraints).
Timeline
The inception of the EVICT Study planning was in October 2015, with study launch in mid-
2016 and completion by mid-2018. During this time, widespread concerns about EBOV per-
sistence in ocular fluid resulted in multiple eye hospitals ceasing all ocular surgery. Only 4 oph-
thalmologists were in-country to serve approximately 7 million people in Sierra Leone. Besides
increasing eye care capacity through training, additional focus of ongoing work is related to
research on ocular complications in EVD survivors, and eye care training, including ocular
fluid sampling, and infection prevention and control. Other aspects that affected our timeline
was the scarcity of laboratories performing EBOV RT-PCR and the long distance from the
Lowell and Ruth Gess Eye Hospital to the KGH Lassa Fever laboratory, making same-day
RT-PCR analysis not possible. Future studies could include same-day EBOV RT-PCR testing
to avoid delays in surgery while awaiting a negative EBOV RT-PCR result.
Special considerations: Pediatric patients
Cataracts, particularly in very young children, have a high rate of posterior capsular opacifica-
tion, long-term risk of glaucoma, and additional challenges if a EVD survivor has had uveitis
[23,24]. Because of severe inflammation that may ensue following cataract removal, patients
are sometimes left without a lens (i.e. aphakic) and a capsulotomy is required. For this reason,
pediatric cataract surgery is often performed by either a pediatric ophthalmologist or vitreoret-
inal surgeon (i.e. pars plana vitrectomy, lensectomy, and capsulotomy). Currently, no vitreor-
etinal surgical capacity is available in Sierra Leone, and efforts are underway to address this
medical care gap. The availability of anesthesiologist support for pediatric cataract surgery also
presents unique challenges to ensure adequate perioperative measures for safety.
PREVAIL VII: Collaborating with other research programs
While the EVICT Study was ongoing in Sierra Leone, the NIH-funded PREVAIL III Study
was increasingly recognizing cataract, uveitis and visual disability in their longitudinal cohort
of EVD survivors in Liberia [3]. Following conversations with the NIH, John Snow, Inc,
Samaritan’s Purse, and ELWA Hospital in Liberia, we initiated a multiple partnership collabo-
ration, which employed similar principles of the EVICT Study related to facility design with
unidirectional flow, infection prevention and control, a two-phased approach of ocular fluid
sampling followed by cataract surgery. The encouraging twelve-month results following cata-
ract surgery in EVD survivors in Liberia patients were recently reported [25,26].
Conclusions
The EVICT Study provided a unique opportunity to address a timely and unanswered ques-
tion related to whether EBOV may persist in the eye in EVD survivors who were awaiting
vision-restorative surgery. The absence of EBOV RNA by RT-PCR provided reassurance to
the eye surgeons and care team that cataract surgery could be performed in EVD survivors
that there was no evidence of increased risk of Ebola virus exposure to the provider during the
time points assessed. Besides these key conclusions relevant to individual Ebola survivors, the
methodologies detailed in this report emphasize a circumspect approach and high level of
detail required for program implementation in complex environments. Moreover, the numer-
ous partnerships, community engagement, patient care and laboratory workflows, while
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tailored to the resource-limited settings, provided opportunities for collaboration in research
and education for vision health systems strengthening. Lessons learned from the ophthalmic
care of EVD survivors may also have broader application for invasive procedures related to
immune privileged organs for other emerging infectious diseases, including those with ocular
sequelae.
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